0000899243-20-021957.txt : 20200810
0000899243-20-021957.hdr.sgml : 20200810
20200810192539
ACCESSION NUMBER: 0000899243-20-021957
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200806
FILED AS OF DATE: 20200810
DATE AS OF CHANGE: 20200810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rohlen Douglas
CENTRAL INDEX KEY: 0001306344
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 201090761
MAIL ADDRESS:
STREET 1: 3600 HOLLY LANE NORTH, SUITE 40
CITY: PLYMOUTH
STATE: MN
ZIP: 55447
FORMER NAME:
FORMER CONFORMED NAME: Rohlen Duke
DATE OF NAME CHANGE: 20041019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-06
0
0001731831
Eidos Therapeutics, Inc.
EIDX
0001306344
Rohlen Douglas
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO
CA
94104
1
0
0
0
Restricted Stock Units
2020-08-06
4
A
0
4526
0.00
A
Common Stock
4526
4526
D
Stock Option (Right to Buy)
41.42
2020-08-06
4
A
0
21447
0.00
A
2030-08-05
Common Stock
21447
21447
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
The shares of Common Stock underlying the RSUs vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date.
The stock option shall vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date.
/s/ Franco Valle, as Attorney-in-Fact
2020-08-10